| Market Cap | 36.62M | P/E | - | EPS this Y | -24.20% | Ern Qtrly Grth | - |
| Income | -35.03M | Forward P/E | -0.70 | EPS next Y | 29.60% | 50D Avg Chg | -34.00% |
| Sales | 12M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
| Dividend | N/A | Price/Book | 3.36 | EPS next 5Y | - | 52W High Chg | -55.00% |
| Recommedations | 2.00 | Quick Ratio | 0.94 | Shares Outstanding | 2.83M | 52W Low Chg | 31.00% |
| Insider Own | 0.14% | ROA | -53.69% | Shares Float | 410.33M | Beta | 1.40 |
| Inst Own | 13.21% | ROE | - | Shares Shorted/Prior | 38.32K/37.17K | Price | 2.24 |
| Gross Margin | 100.00% | Profit Margin | -291.89% | Avg. Volume | 153,030 | Target Price | 72.00 |
| Oper. Margin | -291.03% | Earnings Date | Aug 9 | Volume | 56,753 | Change | -5.49% |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.